As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Spike Lee Says Denzel Washington Deserved Oscar for ‘Malcolm X' Over Al Pacino: ‘It's Like Basketball, Where the Ref Blows a ...

Some doubt has been cast on the future of pharma firm Novo Nordisk after its ousting... The FTSE 100 opened in the green on Tuesday as shares in Diploma Plc climbed 15 per... US drugmaker Pfizer said ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Jorgensen, who joined in 2017, has had the shortest tenure of all. Danish couple August and Marie Krogh founded Nordsik ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

Trump said that the U.S. pays 10 times more for Novo's Ozempic, which has the same active ingredient as Wegovy but is ...